Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

Alzheimer's disease (AD) is characterized by two major pathological lesions in the brain,
amyloid plaques and neurofibrillary tangles (NFTs) composed mainly of amyloid-β (Aβ) …

Proteolytic removal of membrane protein ectodomains (ectodomain shedding) is a post‐
translational modification that controls levels and function of hundreds of membrane …

The microtubule-associated protein tau and amyloid-β (Aβ) are key players in Alzheimer's
disease (AD). Aβ and tau are linked in a molecular pathway at the post-synapse with tau …

With predictions showing that 131.5 million people worldwide will be living with dementia by
2050, an understanding of the molecular mechanisms underpinning disease is crucial in the …

Parkinson's disease (PD) is characterized by the pathologic aggregation and prion-like
propagation of α-synuclein (α-syn). Emerging evidence shows that fungal infections …

The BDNF mimetic compound 7, 8-dihydroxyflavone (7, 8-DHF), a potent small molecular
TrkB agonist, displays prominent therapeutic efficacy against Alzheimer's disease (AD) …

The amyloid cascade hypothesis has always been a research focus in the therapeutic field
of Alzheimer's disease (AD) since it was put forward. Numerous researchers attempted to …

To date, there is no validated fluid biomarker for tau pathology in Alzheimer's disease, with
contradictory results from studies evaluating the correlation between phosphorylated tau in …

Diabetes is a risk factor for Alzheimer's disease (AD), which is also called type 3 diabetes
with insulin reduction and insulin resistance in AD patient brains. However, the molecular …